angiotensin receptor neprilysin inhibitor (ARNI)
Jump to navigation
Jump to search
Indications
- systolic heart failure Containdications:
- diastolic heart failure[3]
- use in combination with ACE inhibitor or ARB
Adverse effects
- increases serum BNP (but decreases serum NT-proBNP)[2]
More general terms
More specific terms
Components
References
- ↑ AGS Member Forum. May 28, 2018 The latest ACC/AHA/HFSA recommendations for Stage C HFrEF
- ↑ 2.0 2.1 Velazquez EJ, Morrow DA, DeVore AD et al. PIONEER-HF Investigators Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2018 Nov 11. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30415601 https://www.nejm.org/doi/10.1056/NEJMoa1812851
- ↑ 3.0 3.1 Solomon SD, McMurray JJV, Anand IS et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019 Sep 1; PMID: https://www.ncbi.nlm.nih.gov/pubmed/31475794 https://www.nejm.org/doi/10.1056/NEJMoa1908655